| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
Oleic anhydride inhibits sphingosine-induced phosphorylation of p32 in Jurkat T cells when used at concentrations ranging from 30 to 100 μM. As a fatty acid anhydride, it can acylate nucleophilic groups on proteins and other biomolecules, modifying their function. The compound has been used in the synthesis of various phospholipids and triglycerides. Its primary targets include cellular proteins involved in sphingosine signaling pathways. The compound's lipophilic nature allows it to interact with cell membranes and lipid-based signaling molecules. Its ability to inhibit p32 phosphorylation suggests potential immunomodulatory effects.
|
|---|---|
| ln Vitro |
In vitro, oleic anhydride is used as a biochemical reagent and acylation agent. It inhibits sphingosine-induced phosphorylation of p32 in Jurkat T cells at concentrations of 30-100 μM. The compound has been used in the synthesis of various phospholipids and triglycerides. It serves as a lipophilic modifier for the preparation of lipid-based compounds. Cellular assays typically evaluate its effects on cell signaling, phosphorylation events, and lipid metabolism. The compound's ability to modify proteins through acylation makes it valuable for studying post-translational modifications.
|
| ln Vivo |
In vivo data for oleic anhydride is limited, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. As a fatty acid anhydride, it would likely be hydrolyzed to oleic acid in biological systems. Oleic acid is a common dietary fatty acid with various physiological roles. The compound's primary value lies in its use as a chemical reagent for synthesis and modification of lipids and other biomolecules. Specific in vivo data is not available in the public literature.
|
| Enzyme Assay |
In vitro enzyme/receptor binding assays for oleic anhydride are not typically performed, as it is primarily a chemical reagent. The compound is used as an acylation agent and lipophilic modifier. A typical assay involves using the compound in chemical reactions to acylate amines or alcohols. The compound is dissolved in organic solvents such as dichloromethane or THF and used at various concentrations. The resulting acylated products can be evaluated for biological activity. The compound's ability to inhibit sphingosine-induced phosphorylation can be assessed in cell-based assays. IC₅₀ values are calculated from dose-response curves.
|
| Cell Assay |
Cellular assays for oleic anhydride typically evaluate its effects on phosphorylation and cell signaling. A standard protocol involves culturing Jurkat T cells in growth medium at 37°C with 5% CO₂. Cells are treated with varying concentrations of oleic anhydride (30-100 μM) in the presence or absence of sphingosine. Phosphorylation of p32 is assessed by immunoprecipitation and Western blot using phospho-specific antibodies. Cell viability is assessed using trypan blue exclusion or MTT assays. The compound's effects on other signaling pathways can also be evaluated. IC₅₀ values are calculated from dose-response curves.
|
| Animal Protocol |
In vivo animal studies for oleic anhydride are not standard, as it is primarily a research reagent. The compound is classified for research use only and is not intended for human or veterinary therapeutic applications. Any animal studies would be limited to evaluating the compound's effects as a lipophilic modifier or its hydrolysis product, oleic acid. The compound's primary value lies in its use as a chemical reagent for synthesis. Specific in vivo protocols are not available in the public literature.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for oleic anhydride is limited, as it is primarily a research reagent. The compound has a molecular weight of 546.91 g/mol and a molecular formula of C₃₆H₆₆O₃. It is a solid at room temperature with a melting point of 22°C and a flash point of 275°C. The compound is stored refrigerated (0-10°C) under inert gas. It is sensitive to air, moisture, and heat. As an anhydride, it is reactive and will hydrolyze in aqueous environments. Specific ADME data is not available.
|
| Toxicity/Toxicokinetics |
Oleic anhydride is classified with signal word "Warning". Hazard statements include H315 (causes skin irritation) and H319 (causes serious eye irritation). Precautionary statements include P264 (wash skin thoroughly after handling), P280 (wear protective gloves/eye protection/face protection), P302+P352 (if on skin: wash with plenty of water), P337+P313 (if eye irritation persists: get medical advice/attention), P305+P351+P338 (if in eyes: rinse cautiously with water for several minutes), P362+P364 (take off contaminated clothing and wash before reuse), and P332+P313 (if skin irritation occurs: get medical advice/attention). The compound should be stored refrigerated under inert gas away from air and moisture.
|
| Additional Infomation |
Oleic anhydride (cis-9-Octadecenoic anhydride, CAS 24909-72-6) is a biochemical reagent with the molecular formula C₃₆H₆₆O₃. It is a symmetric, unsaturated long-chain fatty acid anhydride used as an acylation agent and lipophilic modifier. The compound inhibits sphingosine-induced phosphorylation of p32 in Jurkat T cells and has been used in the synthesis of phospholipids and triglycerides. It is classified as a research-use-only compound not intended for diagnostic or therapeutic purposes. The compound is available from multiple commercial suppliers.
|
| Molecular Formula |
C36H66O3
|
|---|---|
| Molecular Weight |
546.91
|
| Exact Mass |
546.501
|
| CAS # |
24909-72-6
|
| PubChem CID |
5369123
|
| Appearance |
Colorless to light yellow <22.2°C solid powder,>22.2°C liquid
|
| Density |
0.88
|
| Boiling Point |
200-215 °C11 mm Hg(lit.)
|
| Melting Point |
22-24 °C(lit.)
|
| Flash Point |
>230 °F
|
| Vapour Pressure |
8.57E-15mmHg at 25°C
|
| Index of Refraction |
1.471
|
| LogP |
12.131
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
32
|
| Heavy Atom Count |
39
|
| Complexity |
528
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O(C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C(/[H])=C(/[H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O)C(C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C(/[H])=C(/[H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H])=O
|
| InChi Key |
OCNZHGHKKQOQCZ-CLFAGFIQSA-N
|
| InChi Code |
InChI=1S/C36H66O3/c1-3-5-7-9-11-13-15-17-19-21-23-25-27-29-31-33-35(37)39-36(38)34-32-30-28-26-24-22-20-18-16-14-12-10-8-6-4-2/h17-20H,3-16,21-34H2,1-2H3/b19-17-,20-18-
|
| Chemical Name |
[(Z)-octadec-9-enoyl] (Z)-octadec-9-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8285 mL | 9.1423 mL | 18.2845 mL | |
| 5 mM | 0.3657 mL | 1.8285 mL | 3.6569 mL | |
| 10 mM | 0.1828 mL | 0.9142 mL | 1.8285 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
